CE vs LYB: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CE is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CE and LYB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CE and LYB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Celanese Corporation makes chemicals in two very different businesses. Its Acetyl Chain segment produces acetic acid, vinyl acetate monomer, acetate tow and related derivatives, largely commodity molecules sold on price and cost position, and it generated about ~$2.4B of net sales in the first half of 2026. Engineered Materials, the larger half at roughly ~$2.8B of first-half sales, sells specialty polymers, nylon, elastomers and compounds into automotive, medical, electronics and industrial applications where formulations are specified into a customer's part. Around ~11,400 employees run the plant network, which spans North America, Europe and Asia, with a large equity-affiliate presence in China.

Full CE guide

LyondellBasell Industries is a Netherlands-domiciled, US-listed multinational and one of the largest plastics, chemicals, and refining companies in the world. Its business is organized around Olefins and Polyolefins in the Americas and in Europe/Asia/International, an Intermediates and Derivatives segment, Advanced Polymer Solutions, and a Refining operation the company has been winding down. The core products are the building blocks of everyday plastics (polyethylene and polypropylene) plus propylene oxide, oxyfuels, and other intermediates, so results move with feedstock costs, product spreads, and regional demand rather than with a single end market.

Full LYB guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CE drivers: Deleveraging through cash and asset sales; Acetyl Chain pricing and regional supply dislocation.
• LYB drivers: Cycle recovery in polyolefins; Portfolio reshaping and refining exit.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Leverage dominates the risk list. For LYB, lYB is deeply cyclical, so a prolonged glut in global petrochemical capacity, especially new supply from the Middle East and China, can keep polyolefin spreads compressed and earnings depressed.

Pick CE if you believe its drivers more; LYB if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CE and LYB guides.

CE. Two very different valuations sit on the same company. Equity holders pay roughly half of trailing sales, which looks cheap until the ~$10.6B of net debt is added and the whole enterprise prices at about ~1.7x sales, a fairly ordinary multiple for a chemical producer in a soft cycle. Free cash flow of roughly ~$708M over the trailing twelve months is what services the debt, and first-half operating cash of ~$285M came in below the prior year on a large working-capital build in receivables.

LYB. LYB reported Q1 2026 revenue of roughly $7.2 billion, down about 6% year over year, with adjusted EPS of ~$0.49 beating low expectations and adjusted EBITDA of ~$615 million. Trailing GAAP earnings have been depressed by the chemicals downturn, so the stock trades on a low price-to-sales multiple and a recovering forward earnings estimate rather than a clean trailing P/E. The mid-single-digit dividend yield reflects the February 2026 payout recalibration.

Headline figures (approximate, August 2026): CE shows revenue (ttm) ~$9.7B, net income (ttm) ~-$1.2B, driven by goodwill and asset impairments, market cap ~$4.8B at roughly ~$44 per share, net debt ~$10.6B (total debt ~$12.0B less cash ~$1.4B); LYB shows share price ~$62, market cap ~$19.5B, revenue (ttm) ~$30B, q1 2026 adjusted eps ~$0.49.

CE and LYB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CE and LYB exposure against your real portfolio. It is not an investment adviser.